Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.

Cell cycle kinase inhibitors have advanced into clinical trials in oncology. One such molecule, JNJ-7706621, is a broad-spectrum inhibitor of the cyclin-dependent kinases and Aurora kinases that mediate G(2)-M arrest and inhibits tumor growth in xenograft models. To determine the putative mechanisms of resistance to JNJ-7706621 that might be encountered in the clinic, the human epithelial cervical carcinoma cell line (HeLa) was exposed to incrementally increasing concentrations of JNJ-7706621. The resulting resistant cell population, designated HeLa-6621, was 16-fold resistant to JNJ-7706621, cross-resistant to mitoxantrone (15-fold) and topotecan (6-fold), and exhibited reduced intracellular drug accumulation of JNJ-7706621. ABCG2 was highly overexpressed at both the mRNA ( approximately 163-fold) and protein levels. The functional role of ABCG2 in mediating resistance to JNJ-7706621 was consistent with the following findings: (a) an ABCG2 inhibitor, fumitremorgin C, restored the sensitivity of HeLa-6621 cells to JNJ-7706621 and to mitoxantrone; (b) human embryonic kidney-293 cells transfected with ABCG2 were resistant to both JNJ-7706621 and mitoxantrone; and (c) resistant cells that were removed from the drug for 12 weeks and reverted to susceptibility to JNJ-7706621 showed near-normal ABCG2 RNA levels. ABCG2 is likely to limit the bioavailability of JNJ-7706621 because oral administration of JNJ-7706621 to Bcrp (the murine homologue of ABCG2) knockout mice resulted in an increase in the plasma concentration of JNJ-7706621 compared with wild-type mice. These findings indicate that ABCG2 mediates the resistance to JNJ-7706621 and alters the absorption of the compound following administration.
AuthorsJennifer A Seamon, Catherine A Rugg, Stuart Emanuel, Anna Maria Calcagno, Suresh V Ambudkar, Steven A Middleton, Jeannene Butler, Virna Borowski, Lee M Greenberger
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 5 Issue 10 Pg. 2459-67 (Oct 2006) ISSN: 1535-7163 [Print] United States
PMID17041089 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
Chemical References
  • ABCG2 protein, human
  • Abcg2 protein, mouse
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • JNJ-7706621
  • Neoplasm Proteins
  • Triazoles
  • Aurora Kinases
  • Protein-Serine-Threonine Kinases
  • Cyclin-Dependent Kinases
  • ATP-Binding Cassette Transporters (biosynthesis, genetics, physiology)
  • Administration, Oral
  • Animals
  • Antineoplastic Agents (pharmacokinetics, pharmacology)
  • Aurora Kinases
  • Biological Availability
  • Cyclin-Dependent Kinases (antagonists & inhibitors)
  • Drug Resistance, Neoplasm
  • Enzyme Inhibitors (pharmacology)
  • HeLa Cells
  • Humans
  • Mice
  • Mice, Knockout
  • Neoplasm Proteins (biosynthesis, physiology)
  • Protein-Serine-Threonine Kinases (antagonists & inhibitors)
  • Triazoles (pharmacokinetics, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: